S. 1551 · 109th Congress
Protecting Free Trade in Pharmaceuticals Act of 2005
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 109th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
VitterSponsor2 cosponsors · 1 D, 1 R
2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Protecting Free Trade in Pharmaceuticals Act of 2005 - Amends the Bipartisan Trade Promotion Authority Act of 2002 to include among the overall trade negotiating objectives of the United States avoiding negotiating trade agreements that could restrict, or be interpreted to restrict, the access of consumers in the United States to pharmaceutical imports from…
What it does: CRS summary · Introduced in Senate · Jul 28, 2005
Protecting Free Trade in Pharmaceuticals Act of 2005 - Amends the Bipartisan Trade Promotion Authority Act of 2002 to include among the overall trade negotiating objectives of the United States avoiding negotiating trade agreements that could restrict, or be interpreted to restrict, the access of consumers in the United States to pharmaceutical imports from countries with a pharmaceutical infrastructure that is equivalent, or superior, to that of the United States: (1) by or through the use and development of the doctrine of international patent exhaustion, as interpreted or applied by U.S. courts on the enactment of this Act; or (2) by making it a violation for the United States to enact legislation permitting pharmaceutical imports without the consent of patent owners when the products involved have been sold outside the United States.
Prohibits the U.S. Trade Representative (USTR) from: (1) entering into a bilateral or multilateral trade agreement that, with respect to the importation of pharmaceutical products without the consent of the patent owners, includes provisions identical or similar to the provisions of the United States-Singapore Free Trade Agreement, the United States-Australia Free Trade Agreement, or the United States-Morocco Free Trade Agreement; or (2) negotiating an agreement or understanding with respect to any of such provisions.
Requires the USTR, with respect to the advisory committee on matters relating to intellectual property, to ensure that, for each meeting that relates or potentially relates to the importation of pharmaceutical products into the United States, at least 10% of the committee members represent the interests of consumers of such products.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Protecting Free Trade in Pharmaceuticals Act of 2005
Latest action (Jul 28, 2005): Read twice and referred to the Committee on Finance.
Policy area: Foreign Trade and International Finance · Origin: Senate · Introduced: Jul 28, 2005
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.